{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:39:13Z","timestamp":1792539553072,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009827","name":"Alexandria University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009827","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the population of patients in the intensive care unit (ICU), most studies compared the use of atypical antipsychotics, such as quetiapine, with the use of traditional haloperidol in patients with delirium of various forms and etiologies. The role of such agents in patients with hyperactive delirium is not fully understood. This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on the Delirium Rating Scale-Revised-98 (DRS-R-98), length of stay in the ICU, and mortality in critically ill patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred adult patients diagnosed with hyperactive delirium were randomly assigned to receive either oral quetiapine (25\u201350\u00a0mg\/day) or haloperidol (1\u20132\u00a0mg\/day). The response, defined as \u201ca DRS-R-98 severity score reduction from baseline of 50% or more\u201d and a DRS-R-98 severity score of 12 or less without relapse, was the primary outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of all patients was 68\u2009\u00b1\u20096\u00a0years. The study population\u2019s overall response rate was 92%. Response rates for the two groups were remarkably equal (<jats:italic>p<\/jats:italic>\u2009=\u20090.609). Secondary outcomes were comparable in both groups, such as ICU mortality (<jats:italic>p<\/jats:italic>\u2009=\u20090.496), in-hospital mortality (<jats:italic>p<\/jats:italic>\u2009=\u20090.321), in-hospital stay (<jats:italic>p<\/jats:italic>\u2009=\u20090.310), and the need for mechanical ventilation (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.99). But the quetiapine group showed a statistically reduced mean ICU stay (10.1\u2009\u00b1\u20092.0 vs. 11.7\u2009\u00b1\u20092.6\u00a0days, <jats:italic>p<\/jats:italic>\u2009=\u20090.018) and increased sleeping hours per night (<jats:italic>p<\/jats:italic>\u2009=\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Quetiapine may be equally as effective as haloperidol in treating the symptoms of hyperactive delirium in critically ill patients, with no mortality benefit.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12028-024-01948-w","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T20:18:47Z","timestamp":1712002727000},"page":"550-557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium: Randomized Controlled Trial"],"prefix":"10.1007","volume":"41","author":[{"given":"Tamer","family":"Zakhary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Luttfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Montasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fifth Edition. American Psychiatric Pub; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"2","key":"1948_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00134-013-3192-5","volume":"40","author":"IJ Zaal","year":"2014","unstructured":"Zaal IJ, Slooter AJC. Light levels of sedation and DSM-5 criteria for delirium. Intensive Care Med. 2014;40(2):300.","journal-title":"Intensive Care Med"},{"key":"1948_CR3","doi-asserted-by":"publisher","first-page":"h2538","DOI":"10.1136\/bmj.h2538","volume":"350","author":"JI Salluh","year":"2015","unstructured":"Salluh JI, Wang H, Schneider EB, Nagaraja N, Yenokyan G, Damluji A, et al. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015;350:h2538.","journal-title":"BMJ"},{"issue":"1","key":"1948_CR4","doi-asserted-by":"publisher","first-page":"e85332","DOI":"10.1371\/journal.pone.0085332","volume":"9","author":"ICT Almeida","year":"2014","unstructured":"Almeida ICT, Soares M, Bozza FA, Shinotsuka CR, Bujokas R, Souza-Dantas VC, et al. The impact of acute brain dysfunction in the outcomes of mechanically ventilated cancer patients. PLoS ONE. 2014;9(1):e85332.","journal-title":"PLoS ONE"},{"issue":"11","key":"1948_CR5","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.4088\/JCP.v64n1106","volume":"64","author":"Y Sasaki","year":"2003","unstructured":"Sasaki Y, Matsuyama T, Inoue S, Sunami T, Inoue T, Denda K, et al. A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry. 2003;64(11):1316\u201321.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"1948_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/00048674.2011.543411","volume":"45","author":"S Boettger","year":"2011","unstructured":"Boettger S, Friedlander M, Breitbart W, Passik S. Aripiprazole and haloperidol in the treatment of delirium. Aust N Z J Psychiatry. 2011;45(6):477\u201382.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"1948_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","volume":"41","author":"J Barr","year":"2013","unstructured":"Barr J, Fraser GL, Puntillo K, Ely EW, G\u00e9linas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263\u2013306.","journal-title":"Crit Care Med"},{"issue":"6","key":"1948_CR8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1017\/S1478951516001176","volume":"15","author":"S Boettger","year":"2017","unstructured":"Boettger S, Nu\u00f1ez DG, Meyer R, Richter A, Fernandez SF, Rudiger A, et al. Delirium in the intensive care setting: a reevaluation of the validity of the CAM-ICU and ICDSC versus the DSM-IV-TR in determining a diagnosis of delirium as part of the daily clinical routine. Palliat Support Care. 2017;15(6):675\u201383.","journal-title":"Palliat Support Care"},{"issue":"2","key":"1948_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1176\/jnp.13.2.229","volume":"13","author":"PT Trzepacz","year":"2001","unstructured":"Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci. 2001;13(2):229\u201342.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"3","key":"1948_CR10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5498\/wjp.v6.i3.365","volume":"6","author":"S Grover","year":"2016","unstructured":"Grover S, Mahajan S, Chakrabarti S, Avasthi A. Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World J Psychiatry. 2016;6(3):365\u201371.","journal-title":"World J Psychiatry"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"657","DOI":"10.2147\/DDDT.S45575","volume":"7","author":"B Maneeton","year":"2013","unstructured":"Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Des Devel Ther. 2013;7:657.","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"1948_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1046\/j.1479-8301.2003.00012.x","volume":"3","author":"K Omura","year":"2003","unstructured":"Omura K, Amano N. Clinical experience of quetiapine in 24 elderly patients with delirium. Psychogeriatrics. 2003;3(2):69\u201372.","journal-title":"Psychogeriatrics"},{"issue":"1","key":"1948_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0891988702250533","volume":"16","author":"KY Kim","year":"2003","unstructured":"Kim KY, Bader GM, Kotlyar V, Gropper J. Treatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol. 2003;16(1):29\u201331.","journal-title":"J Geriatr Psychiatry Neurol"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-01948-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-024-01948-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-024-01948-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T17:10:08Z","timestamp":1725556208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-024-01948-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1007\/s12028-024-01948-w","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares that there are no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"ClinicalTrials.gov: NCT05690698.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"We confirm compliance with Ethical approval and informed consent for human studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\/informed consent"}}]}}